BI 14332

Drug Profile

BI 14332

Alternative Names: BI-14332-CL; BI14332

Latest Information Update: 14 Aug 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antihyperglycaemics; Piperidines; Pyridines; Xanthines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 07 Aug 2014 Discontinued - Phase-I for Type-2 diabetes mellitus in Germany (PO)
  • 30 Nov 2006 Boehringer Ingelheim initiates enrolment in a phase I trial for Type-2 diabetes mellitus in Germany (NCT02212925)
  • 30 Nov 2006 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02212938)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top